Under these licensing agreements, EraGen will have access to Illumina’s BeadXpress platform for the continued development and commercialisation of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode-PLx technology.

The company said that the partnership is part of EraGen’s strategy to continue to expand its commercial efforts in the molecular diagnostics market.

Irene Hrusovsky, president and CEO of EraGen, said: “We are very excited by the opportunities this partnership presents to EraGen. Our newly formed relationship with Illumina further validates our MultiCode technology’s versatile application in the development and commercialisation of molecular-based assays for the clinical market.

“We will continue to bring to market innovative, high-value molecular diagnostic tests and solutions through strategic platform partnerships and the advancement of a broad product pipeline that is responsive to our customers’ needs.”

Greg Heath, senior vice president and GM of diagnostic division at Illumina, said: “We look forward to seeing the delivery of innovative solutions through the combination of Illumina and EraGen technologies. We view this agreement as a first step toward advancing healthcare through leading-edge molecular tools.”